Celestica is a pass for now, says CIBC Capital Markets

Celestica (Celestica News, Stock Quote, Chart TSX, NYSE:CLS) has been on a downward trend for a couple of years now, but the electronics manufacturing services provider just came in with a quarter that met the consensus expectation. And as the company continues its buyback program, questions have arisen regarding whether Celestica should stay a public company.

That question, specifically, came from Todd Coupland, managing director at CIBC Capital Markets.

Celestica reported its second quarter ended June 30, 2019, on Wednesday, coming in with revenue of $1.45 billion, down from $1.70 billion a year prior but within management’s guidance of $1.4 to $1.5 billion. The company’s Q2 EPS was $0.12 per share, also down from $0.29 per share last year. (All figures in US dollars.)

Both revenue and EPS were in line with analysts’ estimates, however, a good sign for a company that is attempting to right the ship and bring up its share price. CLS is down 22 per cent year-to-date.

On the company’s earnings call on Wednesday, Coupland asked management about its share buyback program, which for Celestica, a long-ago spinoff off IBM, has been cutting down the number of outstanding shares through a multi-year strategy.

Coupland said, “You’re buying a lot of stock back. Your valuation is low here. Does the board think about whether or not it makes sense for Celestica to stay public, given all these transition points and not being terribly well-received by the overall public market?”

In reply, Celestica president and CEO Rob Mionis said, “As a leadership team and as a board, we always look for various ways to return value to our shareholders. Right now, we’re committed to our current strategy. We believe it’s sound. We believe it’s working, albeit it’s not progressing as fast as we’d like, which is being largely driven by the market headwinds we have in capital equipment and to some extent communications. We always look at a wide variety of ways to increase shareholder value.”

In late April, Coupland dropped his rating on CLS from “Outperformer” to “Neutral” while lowering his share price from $11.50 to $8.50 per share.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cls
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

34 mins ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

3 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

4 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

4 days ago